NYSE: LLY

Explore the latest insights on NYSE: LLY and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of NYSE: LLY’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise
CompanyDeals

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Ltd. (NYSE: BHVN) announced that it has entered into a strategic licensing and collaboration agreement with Japan's Ono Pharmaceutical Co., Ltd. (TYO: 4528). Under the agreement, Ono will obtain…

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Huadong Medicine's Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Huadong Medicine’s Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments

Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

Company

Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024

CompanyDrug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management

CompanyDrug

Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial

CompanyDeals

Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal

CompanyDrug

Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval

CompanyDrug

Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals

Show More